Preclinical results presented at the American Association for Cancer Research's Pancreatic Cancer: Progress and Challenges Conference (held June 18-21, 2012 at Lake Tahoe, USA), unveiled a chemotherapeutic agent, MEK 1/2 inhibitor BAY 86-9766, to help understand the progression of pancreatic cancer. Using mice as test subjects, researchers at the Technical University in Munich have shown that MEK 1/2 "led to dramatic tumor shrinkage after only one week of treatment." While this study is thus far only in the preclinical stage, results are promosing and may lead to an improved course of treatment for patients afflicted with pancreatic cancer.
To read more about the MEK 1/2 inhibitor, click here.
No comments:
Post a Comment